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Open Forum Infectious Diseases
MAJOR ARTICLE
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Background. In 2018, the Clinical Microbiology Laboratory at our institution adopted updated daptomycin Enterococcus–susceptible dose-dependent breakpoints. While the introduction of susceptible dose-dependent (SDD) was intended to guide practice
toward optimal dosing, the understanding and application of daptomycin SDD breakpoints for enterococci were unknown.
Methods. This mixed-methods study combined a clinician survey with a retrospective pre–post prescribing analysis. An 8-question survey was distributed to infectious diseases (ID) and internal medicine (IM) clinicians. A retrospective chart review of hospitalized adults with infections due to Enterococcus spp. was conducted before (pre-SDD) and after (post-SDD) adoption of SDD
reporting for enterococci.
Results. Survey response rates were 40 of 98 (41%) for IM and 22 of 34 (65%) for ID clinicians. ID clinicians scored significantly
higher than IM clinicians in knowledge of SDD. Chart review of 474 patients (225 pre- vs 249 post-SDD) showed that daptomycin
dosage following susceptibility testing was significantly higher post-SDD compared with pre-SDD (8.5 mg/kg vs 6.4 mg/kg; P < .001)
with no difference in empiric dosing (6.3 mg/kg vs 6.2 mg/kg; P = .67). Definitive daptomycin use varied between the pre- and postSDD periods (35.1% vs 16.9%; P < .001).
Conclusions. The survey revealed that ID clinicians placed more importance on and had more confidence in the SDD category
over IM clinicians. SDD reporting was associated with a change in definitive daptomycin dosing. ID specialist involvement is recommended in the care of infections due to enterococci for which daptomycin is reported as SDD given their expertise.
Keywords. antimicrobial stewardship; daptomycin; Enterococcus; microbial sensitivity tests.
Daptomycin is a broad-spectrum, cyclic lipopeptide used to
treat serious infections caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA)
and Enterococcus species [1]. Studies have demonstrated
daptomycin treatment failure in enterococci with elevated
minimal inhibitory concentrations (MICs), leading to concerns that standard doses of 4–6 mg/kg may not attain pharmacodynamic targets for select enterococci. In 2018, the
Clinical and Laboratory Standards Institute (CLSI) approved
a susceptible dose-dependent (SDD) breakpoint range of
2–4 mcg/mL for Enterococcus spp., which was subsequently
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published in the M100 guidelines in 2019; the SDD breakpoints were based on a dosage regimen of 8–12 mg/kg administered every 24 hours for serious infections due to enterococci
[2–6]. In 2020, the CLSI again revised the daptomycin breakpoints [3, 5].
While the SDD category is intended to guide practice toward
optimal dosing of daptomycin, it is unknown if the breakpoint
changes and introduction of the SDD category have influenced clinical practice. We performed a mixed-methods study
to assess infectious diseases (ID) and internal medicine (IM)
clinicians’ understanding of daptomycin SDD as it relates to enterococci and its practice implications.
METHODS

The study was conducted at an academic medical center where
daptomycin is restricted to use for MRSA and vancomycinresistant Enterococcus (VRE) infections, situations of vancomycin intolerance, empiric therapy for neutropenic fever in
VRE-colonized patients, or in accordance with ID consultation.
All daptomycin orders are reviewed by antimicrobial stewardship program personnel on Monday–Friday as part of the
Daptomycin SDD Understanding/Application • OFID • 1
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Data Collection

The Mayo Clinic Survey Center distributed the survey via
email using Qualtrics Survey Software. The parameters of
study participation were provided in an introductory email,
which outlined the purpose of the survey, the approach to protecting respondent confidentiality, and the voluntary nature of
involvement. After the initial distribution email, up to 4 automated reminder emails were sent. Respondents were entered in
a drawing to receive 1 of 6 remunerations (3 per each specialty).
Participants could leave questions unanswered. Any surveys left
unfinished at the date of closure were still collected and available answers included in data analysis. Survey responses were
analyzed for the percentage of knowledge questions answered
correctly, the attitudes of clinicians were assessed with Likert
scale responses, and demographic information of survey participants was collected. Survey results were de-identified for
analysis.
Statistical Analysis

The responses to survey questions were summarized using frequencies and percentages. Questions on the Likert scale were
compared between IM and ID clinicians using Wilcoxon ranksum tests. The remaining responses were compared between
clinician groups using either a chi-square or Fisher exact test,
as appropriate. All tests were 2-sided, and P values ≤.05 were
considered statistically significant. All analyses were performed
using SAS, version 9.4 (SAS Institute, Inc., Cary, NC, USA).

Patient Consent

The Institutional Review Board deemed this study exempt. This
study does not include factors necessitating patient consent.
Study Design

This study was divided into 2 parts: clinical survey and retrospective chart review.
Part 1: Clinician Survey

Recruitment

The survey was open from January through February 2021
to fully licensed IM and ID physicians and advanced practice
providers as identified through the local human resources department and confirmed by the study team. Medical residents,
fellows, pharmacists, and clinical microbiologists were excluded.
The survey included 4 knowledge-based questions, 4 attitudebased questions, and 3 demographic questions (Supplementary
Data 2). Knowledge-based questions were designed to cover the
meaning of SDD in general, then the meaning of SDD applied to
daptomycin specifically, and case-based questions were meant
to assess the application of this knowledge. Attitude-based
questions were designed to assess clinicians’ self-perceived understanding and application of SDD. Before distribution, the
survey questions were independently reviewed by each member
of the study team and by the Mayo Clinic Survey Center.
2 • OFID • Adema et al

Part 2: Retrospective Chart Review

Population

A retrospective chart review was conducted from 1 year pre–
SDD reporting (5/1/2017–5/1/2018) to 1 year post–SDD implementation (9/1/2019–9/1/2020). Time periods were chosen to
allow adequate time for full implementation of SDD reporting.
Inclusion criteria were inpatient admission at the study site and
Enterococcus spp. cultured from sterile sources or VRE from
urine with a daptomycin MIC of 2 or 4 mcg/mL. Patients were
excluded for the following reasons: age <18 years, presence of
pulmonary infection, current incarceration, currently pregnant,
or lack of Minnesota research authorization on file.
Data Collection

A microbiology report identifying patients with an Enterococcus
spp. isolate with daptomycin susceptibilities performed within
the study time frame was reviewed for inclusion and exclusion criteria. The following were collected on patients who
met study criteria: demographics, height/weight/laboratory
values at the time of culture sample collection, concomitant
use of serotonergic medications and/or statin therapy, species
of Enterococcus when applicable, antimicrobial susceptibilities,
poly- or monomicrobial infection, and empiric and definitive
antibiotics administered. The doses (ie, total daily doses and
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routine prospective audit with intervention program. Thus,
ID clinician involvement in patient cases where daptomycin
is used is common at this institution. Of note, daptomycin is
dosed locally using adjusted body weight. Since September
2018, susceptibility testing results have been provided with a report comment in the electronic health record (EHR) outlining
appropriate dosages (ie, 8–12 mg/kg) for the daptomycin SDD
category. At our institution, the SDD interpretive category is
reported alongside the MIC, similar to the reporting of other
interpretive categories. On the isolate report, the dosage guidance is provided as a footnote stating, “SDD for daptomycin in
the treatment of Enterococcus sp. is based on a higher dosage
of 8–12 mg/kg in adults. Infectious Diseases consultation recommended if daptomycin is used in this setting.” During
the preperiod, MICs were interpreted according to the 2018
CLSI guidelines, and the post-SDD time period used the 2019
guidelines (Supplementary Data 1) [2, 3]. Isolates were identified to the species level (via MALDI-TOF [matrix-assisted
laser desorption/ionization time-of-flight] MS), and the Etest
(bioMérieux) was performed and was reported in doubling dilutions, with the exception that in the preperiod urinary isolates
were identified only to the genus level. Daptomycin susceptibility testing was performed on sterile sources and on VRE
isolated from the urine and was not reported on lower respiratory isolates. The presence of van A/B gene was reported from
Biofire Diagnostic Film Array blood culture panel.

questions assessing case-based application (Questions 7 and 8)
of knowledge (Table 1). In total, more ID clinicians answered
all 4 knowledge-based questions correctly compared with IM
clinicians (Table 1).

Statistical Analysis

Attitude-Based Questions

Data were summarized using frequencies and percentages for
categorical variables and medians and interquartile ranges
(IQRs) for continuous variables. Comparisons were made between time periods using the chi-square test or Fisher exact test
for categorical data and the Wilcoxon rank-sum test for continuous data. Univariable and multivariable logistic regression
was used to assess the association between time period and
daptomycin prescribing rates. In the multivariable model, we
adjusted for serotonergic medication use, allergies, statin use,
and ID consultation. These variables were chosen a priori.
Associations were summarized using odds ratios (ORs) and
95% CIs. A multivariable linear regression model was used to
evaluate the variables of time period (pre or post), ID consultation, culture source, and MIC on daptomycin dosing. All tests
were 2-sided, and P values ≤.05 were considered statistically
significant. All analyses were performed using SAS, version 9.4
(SAS Institute, Inc., Cary, NC, USA).
RESULTS
Part 1: Clinician Survey

Clinician Recruitment

Thirty-five ID clinicians and 111 IM clinicians were identified as potential survey participants based on an organizational
report provider by our institution’s department of human resources. One and 13 clinicians from ID and IM were excluded,
respectively, due to inactive practice status. This resulted in 34
ID clinicians and 98 IM clinicians who were approached as possible survey participants. The response rate among ID clinicians
was 65% (22/34), and among IM clinicians it was 41% (40/98).
Of all clinicians who started the survey, there were a total of 6
surveys (4 from IM and 2 from ID) that were left with at least
1 incomplete response. There were no significant differences in
credentials (MD/DO, APRN, PA) between ID and IM clinicians
(P = .17) or in the years of experience in their respective specialty training (P = .12).
Knowledge-Based Questions

Overall, ID clinicians scored significantly higher in 3 of 4
knowledge-based questions compared with IM (Figure 1A). The
single multiple-choice question (Question 1, Supplementary
Data 2) in which IM and ID clinicians performed similarly related to the ability to correctly define SDD, where 36 of 39 (92%)
IM and 20/21 (95%) ID clinicians answered correctly (P = .99).
More ID clinicians than IM clinicians correctly answered the
question focused on dose selection for treatment of infections
due to isolates reported as SDD (Questions 5 and 6) and the

Based on the 4 attitude questions (Supplementary Data 2), ID
clinician responses significantly differed from IM clinician responses (Figure 1B). ID clinicians answered “agree” or “strongly
agree” to attitude-based questions at a higher rate, indicating
that they placed more importance on and had more confidence
in using the SDD category compared with IM clinicians (Figure
1B).
Part 2: Retrospective Chart Review

Demographics

A total of 2118 enterococcal isolates were identified by microbiology report; these included all Enterococcus spp. with
daptomycin susceptibility testing results from 5/1/2017 to
5/1/2018 and 9/1/2019 to 9/1/2020. Following application of inclusion/exclusion criteria (Figure 2), 474 patients were included
in the final analysis—225 patients in the pre-SDD period and
249 patients in the post-SDD period. Patient demographics
were similar between the 2 groups, with the exception of the
median age being higher in the post-SDD group (65 years vs 62
years; P = .022) (Table 2A).
Enterococci Characteristics

A difference in the number of Enterococcus spp. was identified
between the pre- and post-SDD periods (Table 2B). There was a
higher number of Enterococcus faecium isolates observed in the
post-SDD period (55.1% vs 66.7%). Penicillin susceptibility was
significantly increased in the post-SDD period as compared
with the pre-SDD period, and no difference in linezolid susceptibility patterns was noted. No statistically significant difference was identified in vancomycin susceptibilities in the pre- vs
post-SDD cohorts. There was a significantly higher percentage
of isolates with a daptomycin MIC of 4 mcg/mL in the postSDD period.
Antibiotic Administration

There is a notable distinction when taking into consideration
whether a susceptibility report was available at the time of administration. Before susceptibility reporting (ie, empiric antimicrobial administration), daptomycin was used with equal
frequency in the pre- and post-SDD time periods (14.7% vs
14.5%; P = .95). When daptomycin use was empiric, the median dose did not differ between the pre-SDD and post-SDD
periods (6.3 mg/kg vs 6.2 mg/kg; P = .67). After susceptibility
reporting was made available, daptomycin was used significantly less often in the post-SDD time period as compared with
the pre-SDD period (16.9% vs 35.1%; P < .001). When used
Daptomycin SDD Understanding/Application • OFID • 3
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mg/kg doses) of daptomycin given before and after susceptibility results were reported, as well as record of ID consultation. Data were stored in a Research Electronic Data Capture
(REDCap) database.

A

P = .99
100%

92%

95%

P < .001
100%

P < .001

P = .006

95%

90%
80%
70%
56%

60%
50%

44%

40%

31%

30%
20%
10%
0%

SDD meaning
(Question 5)

Patient case dosing
(Question 7)

Daptomycin SDD dosage
range (Question 6)
IM percent correct1

Patient case therapy
decision (Question 8)

ID percent correct2

Percent correct of knowledge-based questions answered correctly

B
100%

P < .001

90%

82%

P = .005
86%

P < .001

P < .001

81%

77%

80%
70%
60%

60%
50%

43%

40%
30%
18%

20%

18%

10%
0%
I understanding meaning of SDD

SDD is important in my
practice

I can interpret SDD

I can apply SDD

IM1 ID2
Percent “Agree” or “Stongly agree” with statement
Figure 1. A, Responses to knowledge-based questions. B, Responses to Likert-scale attitude-based questions. Abbreviations: ID, infectious disease clinicians; IM, internal
medicine clinicians; SDD, susceptible dose-dependent.

for definitive treatment (ie, after susceptibility reports were released), the median daptomycin dose was significantly higher
in the post-SDD group (6.4 mg/kg vs 8.5 mg/kg; P < .001).
Additionally, dosing in the post-SDD period when the isolates
were stratified by MIC displayed a slightly higher dose utilized
in isolates with an MIC of 2 mcg/mL (8.2 mg/kg) vs 4 mcg/mL
(9.0 mg/kg). However, in both the pre- and post-SDD periods,
a trend toward high dosing was observed in isolates with an
MIC of 4 mcg/mL compared with 2 mcg/mL (7.6 mg/kg vs
4 • OFID • Adema et al

6.5 mg/kg). Overall, the median daptomycin dose differed significantly by culture source comparing blood, urine, and other
in the pre period (overall P = .003) but not in the post period
(overall P = .71). ID was consulted in 60.8% of all patients, and
in 93.4% of patient cases when daptomycin was utilized. In both
pre- and post-SDD periods, the median daptomycin dose was
significantly higher when an ID consult was present (pre-SDD
period, 5.2 mg/kg vs 6.4 mg/kg; P = .040; post-SDD period,
6.2 vs 8.7 mg/kg; P = .041). When evaluating cases for which
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70%

Table 1.

Responses to Knowledge-Based Questions
Knowledge-Based Responses Correct by Individual Question
IM Number Correct (%)

ID Number Correct (%)

36/39 (92.3)

20/21 (95.2)

Daptomycin SDD dosage range (Question 6)

22/39 (56.4)

Patient case dosing (Question 7)

16/36 (44.4)

Patient case therapy decision
(Question 8)

11/36 (30.6)

Overall Number Correct (%)

P Value

56/60 (93.3)

.99

21/21 (100.0)

43/60 (71.7)

<.001

19/20 (95.0)

35/56 (62.5)

<.001

14/20 (70.0)

25/56 (44.6)

.006

Overall Performance on Knowledge-Based Questions
IM Clinicians, %

ID Clinicians, %

1 question correct

97.2

100.0

2 questions correct

63.9

100.0

3 questions correct

44.5

95.0

4 questions correct

16.7

65.0

P Value
<.001

Abbreviations: ID, infectious diseases; IM, internal medicine; SDD, susceptible dose-dependent.

daptomycin was utilized, rates of ID specialist involvement were
similar between the 2 time periods. Uni- and multivariable analyses showed a higher likelihood of receipt of daptomycin in the
pre-SDD period or when ID was consulted (Table 3). There was
no significant effect of serotonergic medication use, antibiotic
allergy reported, or statin use on the utilization of daptomycin.
The associated time period (pre vs post) was found to remain
a statistically significant variable when the data were analyzed
using a multivariable linear regression model for daptomycin
dosing (P < .001) (Supplementary Data 3).

Enterococcus isolate
with daptomycin
susceptibility
n = 2118
Isolate from the
predefined study site
n = 1784

Excluded, n = 1310
- MIC <2 or >4 mcg/mL, n = 988
- Second hospitalization, n = 28
- Second isolate in same hospitalization, n = 178
- Age <18 years, n = 4
- Pulmonary source, n = 5
- Not admitted, n = 66
- No MN research authorization on file, n = 41

Included in final
analysis
n = 474

Pre-SDD time period
n = 225

Post-SDD time period
n = 249

Figure 2. Patient recruitment. Abbreviations: MIC, minimum inhibitory concentration; MN, Minnesota; SDD, susceptible dose-dependent.

DISCUSSION

Proper daptomycin dosing for enterococcal infections with
an SDD susceptibility result is an important facet of ensuring
appropriate antibiotic therapy. Despite the release of the new
SDD interpretive criteria several years ago, little is known
about how well this information is understood and practically applied by clinicians. The current study was developed
to evaluate ID and IM clinicians’ understanding and attitudes
toward the SDD interpretive criteria for daptomycin in enterococcal isolates and to assess the integration of this into
real-world clinical practice. The novel mixed-methods study
design allowed us to evaluate current knowledge and attitudes
of clinicians and assess whether changes in practice occurred
following implementation of SDD reporting, thereby allowing
an assessment of both quantitative and qualitative data on the
criteria’s use [7].
In Part 1 of this study, a significant difference was identified
between ID and IM clinicians in both the knowledge of the
SDD interpretive category as it applies to daptomycin and enterococci and the subjective attitudes of utilizing this category.
While this may be anticipated given the additional training that
ID clinicians receive, there are still important observations from
these results. Notably, at an institution such as our study site,
there is guidance provided on the susceptibility report as to how
daptomycin doses should be optimized in the case of an SDD
isolate. Even with the presence of this guidance in clinical practice, IM clinicians were less knowledgeable of the interpretation
of the SDD category when presented with a patient case in the
absence of a guiding statement provided within the patient case.
This observation is potentially of greater importance at institutions without a specialty ID service to assist with antibiotic optimization. In such institutions, the clinical practice may benefit
from increased provider education as well as from pharmacist
involvement in daptomycin dosing.

Daptomycin SDD Understanding/Application • OFID • 5
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SDD meaning
(Question 5)

Table 2.

Part 2 Characteristics
A, Patient Demographics
Pre-SDD Period
(n = 225)

Post-SDD Period
(n = 249)

Total
(n = 474)

P Value

Age
62 (52–71)

65 (57–73)

64 (54–72)

.022
.57

Female
Male

97 (43.1)

101 (40.6)

198 (41.8)

128 (56.9)

148 (59.4)

276 (58.2)

Weight

.16

Median (IQR), kg

78.3 (66.5–91.5)

81.8 (66.8–96.1)

80.1 (66.6–95.2)

26.7 (22.5–31.8)

27.6 (22.9–32)

27.2 (22.8–31.9)

BMI

.28

Median (IQR), kg/m2
Statin use, No. (%)

72 (34.6)

67 (27.2)

139 (30.6)

.10

>1 serotonergic medication, No. (%)

11 (4.9)

15 (6.0)

26 (5.5)

.69

Any antibiotic allergy reported, No. (%)

74 (32.9)

82 (32.9)

156 (32.9)

.99

B, Isolate Species Characteristics & Antibiotic Administration
Pre-SDD Period
(n = 225)

Post-SDD Period
(n = 249)

Total
(n = 474)

Pathogens, No. (%)
Polymicrobial

.82
145 (64.4)

158 (63.5)

303 (63.9)

80 (35.6)

91 (36.5)

171 (36.1)

E. faecalis

67 (29.8)

72 (28.9)

139 (29.3)

E. faecium

124 (55.1)

166 (66.7)

290 (61.2)

25 (11.1)

0 (0)

25 (5.3)

9 (4)

11 (4.4)

20 (4.2)

2 mcg/mL

163 (72.4)

149 (59.8)

312 (65.8)

4 mcg/mL

62 (27.6)

100 (40.2)

162 (34.2)

Monomicrobial

<.001a

Species of Enterococcus, No. (%)

Enterococcus spp.b
Other speciesc
Daptomycin MIC, No. (%)

.004

Linezolid susceptibility, No. (%)
Susceptible
Resistant

P Value

.14
111/112 (99.1)
1/112 (0.9)

240/240 (100)
0/240 (0.0)

351/352 (99.7)
1/352 (0.3)

Penicillin susceptibility, No. (%)
Susceptible

107/225 (47.6)

142/247 (57.5)

249/472 (52.8)

Resistant

118/225 (52.4)

105/247 (42.5)

223/472 (47.2)

124/221 (56.1)

163/248 (65.7)

287/469 (61.2)

Vancomycin susceptibility, No. (%)
Susceptible
Intermediate
Resistant

.092
2/221 (0.9)

1/248 (0.4)

3/469 (0.6)

95/221 (43.0)

84/248 (33.9)

179/469 (38.2)

Empiric antibiotic, No. (%)
Daptomycin

15 (6.7)

8 (3.2)

23 (4.9)

Vancomycin

92 (40.9)

96 (38.6)

188 (39.7)

.081
.6

Piperacillin-tazobactam

85 (37.8)

86 (34.5)

171 (36.1)

.46

Ampicillin

4 (1.8)

1 (0.4)

5 (1.1)

.14

Linezolid

6 (2.7)

6 (2.4)

12 (2.5)

.86

Ampicillin-sulbactam

1 (0.4)

3 (1.2)

4 (0.5)

.37

Vancomycin

137 (60.9)

125 (50.2)

262 (55.3)

.019

Piperacillin-tazobactam

112 (49.8)

115 (46.2)

227 (47.9)

.43

Ampicillin

9 (4)

14 (5.6)

23 (4.9)

.41

Linezolid

19 (8.4)

25 (10)

44 (9.3)

.55
.079

Antibiotics administered during course of therapy, No. (%)

Ampicillin-sulbactam

2 (0.9)

8 (3.2)

10 (2.1)

33 (14.7)

36 (14.5)

69 (14.6)

6.3 (6.1–7.0)

6.2 (6.0–6.8)

6.3 (6.0–7.0)

79 (35.1)

42 (16.9)

121 (25.5)

Daptomycin use before susceptibility reporting, No. (%)
Yes

.95

Daptomycin dose before susceptibility reporting
Median (IQR), mg/kg

.67

Daptomycin use after susceptibility reporting, No. (%)
Yes

<.001

Daptomycin dose after susceptibility reporting
Median (IQR), total, mg/kg

6.4 (6.0–7.1)

8.5 (6.4–10.0)

6.6 (6.1–8.3)

<.001

Median (IQR), excluding Enterococcus identified to genus level only,d mg/kg

6.4 (6.1–7.0)

8.5 (6.4–10.0)

6.5 (6.1–8.3)

<.001

6 • OFID • Adema et al
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Median (IQR), y
Gender

Table 2.

Continued
A, Patient Demographics
Pre-SDD Period
(n = 225)

Post-SDD Period
(n = 249)

Total
(n = 474)

P Value

6.3 (6.0–6.9)

8.2 (6.2–9.4)

6.5 (6.1–8.0)

<.001

Median (IQR), MIC 4 mcg/mL,f mg/kg

6.4 (6.1–7.7)

9.0 (7.9–10.2)

7.6 (6.2–9.0)

.002

Median (IQR), source = blood,g mg/kg

6.9 (6.2–8.3)

8.8 (8.0–10.0)

7.9 (6.4–8.7)

.005

Median (IQR), source = urine,h mg/kg

5.2 (4.3–7.0)

8.6 (5.3–9.8)

6.2 (4.3–9.4)

.20

Median (IQR), source = other,i mg/kg

6.3 (6.0–6.6)

8.3 (6.3–9.7)

6.4 (6.1–7.9)

<.001

Median (IQR), ID consult,j mg/kg

6.4 (6.1–7.2)

8.7 (7.9–10.0)

6.6 (6.1–8.4)

<.001

Median (IQR), no ID consult,k mg/kg

5.2 (5.2–6.0)

6.2 (6.0–8.1)

6.0 (5.2–7.2)

.18

158 (70.2)

130 (52.2)

288 (60.8)

<.001

76 (96.2)

37 (88.1)

113 (93.4)

.088

ID consultation, No. (%)
All patients
Patients receiving daptomycin

Abbreviations: BMI, body mass index; ID, infectious diseases; IM, internal medicine; IQR, interquartile range; MIC, minimum inhibitory concentration; SDD, susceptible dose-dependent.
a

A significant P value indicates an imbalance in the spread of Enterococcus spp. but does not specify between which values a significant difference lies.

b

Isolates not identified to the species level depending on specimen source pre-SDD time period; in post-SDD time period, isolates were routinely identified to the species level regardless
of source.
c

Other species: E. casseliflavus (1), E. gallinarum (12), E. hirae (5), E. mundtii (1), E. raffinosus (1).

d

Pre: n = 76; post: n = 42.

e

Pre: n = 54; post: n = 23.

f

Pre: n = 25; post: n = 19.

g

Pre: n = 25; post: n = 12.

h

Pre: n = 7; post: n = 8.

i

Pre: n = 125; post: n = 159.

j

Pre: n = 76; post: n = 37.

k

Pre: n = 3; post: n = 5.

In Part 2 of this study, a change in practice was observed
in which higher doses of daptomycin were used in definitive
therapy in the post-SDD group. Specifically, the median dose
utilized did fall within the recommended range of 8–12 mg/
kg, albeit on the lower end of the recommended range and with
some patients receiving continued use of 6 mg/kg of daptomycin
despite displaying SDD susceptibility. When distinguishing isolates with an MIC of 2 vs 4 mcg/mL, there was a trend toward
higher dosing being prescribed for the MIC 4 mcg/mL subgroup
(Table 2B). This finding may demonstrate MIC-tailored dosing
in these patient scenarios, recognizing that higher MICs within
the SDD interpretation require increased daptomycin dosing.
Interestingly, before the release of susceptibility results, the dosing
Table 3.

Variable Analyses
Univariable

Multivariable

Odds Ratioa
(95% CI)

P
Value

Adjusted Odds
Ratio
(95% CI)

P
Value

Time period (pre
vs post)

0.38 (0.24–0.58)

<.001

0.50 (0.31–0.80)

.004

Serotonergic
medication use

0.87 (0.34–2.22)

.77

0.96 (0.34–2.73)

.94

Allergy reported

1.36 (0.88–2.08)

.17

1.08 (0.66–1.77)

.77

Statin use

1.02 (0.64–1.62)

.94

0.84 (0.50–1.40)

.50

14.36 (6.81–30.30)

<.001

13.80 (6.20–30.73)

<.001

ID consulted

Abbreviations: ID, infectious diseases; OR, odds ratio.
a

OR >1 means more likely to have had daptomycin administered following susceptibility
reports.

in both periods demonstrates a dosing strategy closer to 6 mg/
kg. Consideration may be given whether there are situations in
which an empiric dosing strategy of 8–12 mg/kg should be indicated to target an Enterococcus sp. with an SDD susceptibility.
This appears to be a limitation of directing antimicrobial dosing
using susceptibility results that are not available empirically.
While the median definitive therapy daptomycin dose was
increased following SDD implementation, the overall rate of
daptomycin administration was decreased. Compared with the
pre-SDD period, there was an increase in both penicillin and
vancomycin-susceptible isolates in the post-SDD period. This
variability in susceptibilities, coupled with provider unfamiliarity surrounding the SDD interpretive criteria or a preference
for use of an antimicrobial reported as susceptible over SDD
(eg, linezolid), may have impacted the agent selected for definitive therapy. A similar finding was seen in a small retrospective
analysis of cefepime SDD Enterobacterales isolates wherein most
infections were treated with a carbapenem instead of cefepime
[8]. However, in that study all cefepime SDD isolates were
dosed in accordance with CLSI guidance, whereas daptomycin
was not always dosed to SDD specifications in our findings.
Interestingly, we did not identify a statistically significant shift
to a single daptomycin alternative for definitive therapy (eg,
linezolid, vancomycin, or ampicillin-based regimens) in the
post-SDD period. This considered, definitive antimicrobial
therapy selection is a multifactorial decision impacted by the
interplay between patient and/or organism characteristics, clinician preferences, and more. Therefore, a singular reason for
Daptomycin SDD Understanding/Application • OFID • 7

Downloaded from https://academic.oup.com/ofid/article/9/1/ofab611/6502316 by Washington University School of Medicine Library user on 04 February 2022

Median (IQR), MIC 2 mcg/mL,e mg/kg

8 • OFID • Adema et al

practices and/or without antimicrobial stewardship guidance
comments to specify dosages upon which the breakpoints were
developed merits further exploration.
CONCLUSIONS

ID clinicians demonstrated better understanding and higher
confidence in daptomycin SDD interpretive criteria for
Enterococcus spp. as compared with IM clinicians. SDD reporting resulted in a modest change in definitive daptomycin
dosing and no change in empiric dosing at our institution. ID
specialist involvement is recommended when daptomycin is
used to treat enterococci with a daptomycin MIC in the SDD
range.
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the decrease in definitive daptomycin use in the post period was
not able to be clearly determined in this study.
Current literature supports the involvement of ID specialists
to aid with antimicrobial management in patients with enterococcal infections. Specifically, ID consultation in the treatment
of enterococcal bacteremia was associated with lower 30-day
mortality compared with patients who did not receive ID consultation, especially when Enterococcus faecium was isolated [9].
An additional retrospective analysis assessed the impact of ID
consultation in children with enterococcal bacteremia [10]. This
analysis showed ID specialist involvement to be associated with
a significant improvement in outcomes, such as higher rates of
appropriate empiric therapy, appropriate definitive therapy, and
increased survival at 1 year [10]. These additional studies emphasize that ID involvement improves patient outcomes for serious enterococcal infections. Our study adds to this literature
by demonstrating the importance of ID specialist involvement
in the selection of optimal daptomycin doses.
This study has several limitations. First, it was conducted at a
single academic medical center and may not be representative
of the knowledge, practices, and resources at other institutions.
Second, the involvement of ID specialists, clinical pharmacists,
and clinical microbiologists in the day-to-day practice may have
impacted chart review results, whereas these clinicians were
excluded from the survey. Third, an interrupted time series is
vulnerable to confounding. Additionally, while survey response
rates were similar to those reported in the literature, there were
fewer participants in the IM group relative to ID. Next, while the
current study evaluated changes and current attitudes in practice, it was not designed to evaluate clinical outcomes. Another
limitation is that this study does not assess the 2020 CLSI revised
daptomycin breakpoints. Our institution has since adopted these
updated breakpoints, but they are not assessed in this study.
The current study was able to identify critical gaps in the understanding and implementation of SDD interpretive criteria
when applied to Enterococcus spp. and daptomycin. Further
studies are needed to evaluate clinical outcomes of both efficacy
and toxicity in patients treated with daptomycin 8–12 mg/kg for
enterococcal infections. With the most recent CLSI guidance on
daptomycin breakpoints, there is now no “susceptible” breakpoint for E. faecium for daptomycin, only “SDD” and “resistant,”
highlighting the importance more than ever of proper understanding and application of SDD [3]. The impact of reporting of
SDD interpretive categories at institutions without ID specialty

